Signal Advisors Wealth LLC Raises Stock Holdings in ResMed Inc. (NYSE:RMD)

Signal Advisors Wealth LLC increased its holdings in ResMed Inc. (NYSE:RMD) by 6.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,611 shares of the medical equipment provider’s stock after acquiring an additional 92 shares during the quarter. Signal Advisors Wealth LLC’s holdings in ResMed were worth $368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of RMD. True Wealth Design LLC increased its position in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 110 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of ResMed during the third quarter valued at $34,000. Capital Performance Advisors LLP purchased a new position in shares of ResMed in the 3rd quarter worth about $60,000. Quest Partners LLC boosted its stake in ResMed by 44.1% in the 2nd quarter. Quest Partners LLC now owns 327 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 100 shares in the last quarter. Finally, Quarry LP grew its position in ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 242 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RMD. Piper Sandler assumed coverage on shares of ResMed in a report on Friday, January 10th. They issued a “neutral” rating and a $252.00 target price for the company. Royal Bank of Canada boosted their target price on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Wolfe Research restated an “underperform” rating and issued a $180.00 target price on shares of ResMed in a report on Wednesday, September 18th. Finally, Baird R W raised shares of ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $233.09.

ResMed Price Performance

NYSE RMD opened at $233.01 on Thursday. The stock has a market cap of $34.20 billion, a price-to-earnings ratio of 30.86, a PEG ratio of 1.73 and a beta of 0.70. ResMed Inc. has a 12 month low of $168.29 and a 12 month high of $260.49. The company’s 50 day moving average is $239.24 and its two-hundred day moving average is $232.06. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.17. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. ResMed’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.64 EPS. As a group, research analysts anticipate that ResMed Inc. will post 9.34 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Thursday, November 7th were paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend was Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is presently 28.08%.

Insider Buying and Selling

In other news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the transaction, the director now owns 81,218 shares of the company’s stock, valued at approximately $19,951,201.70. The trade was a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the transaction, the director now owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,099 shares of company stock valued at $2,719,385. Corporate insiders own 0.71% of the company’s stock.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.